Nazli Dizman, MD, explains that gut microbiome diversities play a large role in modulating response to immunotherapy.
Videos
Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, comment on the role of preoperative endocrine therapy in HR-positive high-risk breast cancer.
Joyce O’Shaughnessy, MD, reviews the case of a 42-year-old woman with node-positive, HR-positive high-risk breast cancer and discusses clinical data from the POETIC and ADAPT clinical trials.
Carole Miller, MD, discusses the REVEAL study which enrolled patients with polycythemia vera at both academic and community practices.
Ghaith Abu-Zeinah, MD, discusses the unmet needs investigational drugs could address for patients with polycythemia vera.
Tracy L. Rose, MD, MPH, discusses ongoing research in bladder cancer that aims to add onto the standard of care and improve patient outcomes.
Cathy Eng, MD, discusses what can be done in order to integrate biomarker testing for anal cancer into clinical practice.
Marcia S. Brose, MD, PhD, concludes by listing some future directions she’d like to see within the treatment landscape, as well unmet needs that she hopes will be considered.
An expert briefly discusses the second-line treatment options for patients with DTC that have progressed on first-line therapy.
A medical professional explains how the size of lung metastases affect the treatment of DTC and clinician decision-making.
Marcia S. Brose, MD, PhD, introduces our second patient case, a 57-year-old man with DTC.
Dr Brose elaborates on treating patients with DTC with lenvatinib, including starting dosage and toxicities/adverse events.
A medical professional discusses Study 211 data and HRQoL analyses for patients with DTC on lenvatinib.
An expert explains the impact of patient age when taking lenvatinib for treatment.
Andrew Wei, MBBS, discusses characteristics associated with long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.
Dr Brose reviews frontline treatment options for radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Dr Brose delves into radioiodine-refractory differentiated thyroid (RR-DTC), from its definition and the clinical molecular markers that impact that refractoriness.
Marcia S. Brose, MD, PhD, introduces our first patient case, a 70-year-old woman with differentiated thyroid cancer (DTC).
John Mascarenhas, MD, summarizes the treatment landscape for myelofibrosis, which now includes of pacritinib.
Naomi B. Haas, MD, discusses the use of VEGF tyrosine kinase inhibitors as neoadjuvant therapy for renal cell carcinoma.
Ursula A. Matulonis, MD, discusses the impact of PARP inhibitors on ovarian cancer treatment.
Prerna Mewawalla, MD, looks back at a decade of advancements in the multiple myeloma space.
Lee Schwartzberg, MD, discusses the concerns of treating patients with early triple-negative breast cancer with immunotherapy.
Jesus Berdeja, MD, discusses the safety profile observed with the newly approved chimeric antigen receptor T-cell therapy, ciltacabtagene autoleucel as observed in the phase 1/2 CARTITUDE-1 clincial trial.
Ronald L. Paquette, MD, discusses how transplant related morbidity and mortality risks differ between age groups for patients with myelodysplastic syndrome.
A panel of breast cancer experts share recommendations for adjuvant chemotherapy and endocrine therapy for a patient with HR-positive breast cancer and discuss approaches to toxicity management to increase adherence to therapy.
Joyce O’Shaughnessy, MD, leads a discussion on SABCS 2021 updates from the SOFT and TEXT trials for premenopausal women with HR-positive breast cancer.
Experts in breast cancer review the case of a 42-year-old woman with grade 2, node-positive invasive ductal carcinoma and discuss updated data from the RxPONDER trial on adjuvant chemotherapy benefit in premenopausal women.
Manali Bhave, MD, discusses the updated results of the MonarchE study of abemaciclib in patients with hormone receptor-positive, HER2-negative, breast cancer.
Melissa M. Hardesty, MD, discusses the challenges faced within the community setting in regard to the treatment landscape for advanced ovarian cancer.